Search Results

Azura Ophthalmics Ltd. today announced that the first patient has been enrolled in the ASTRO study – a Phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of Meibomian Gland Dysfunction (MGD).

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Azura Ophthalmics Ltd. today announced positive topline efficacy and safety results from a Phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of Meibomian Gland Dysfunction (MGD).

Azura Ophthalmics Ltd. today announced that members of management will present at BTIG’s Ophthalmology Day 2022, being held on November 29, and at the Piper Sandler 34th Annual Healthcare Conference, being held from November 29 through December 1.

Azura Ophthalmics Ltd. announced that its executive team will hold 1x1 investor meetings during the Private Company Track of the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2.

Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the formation of its scientific advisory board (SAB).

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations featuring positive efficacy and safety data from a Phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company’s U.S. 11,459,351 patent (the ‘351 patent) was granted by the U.S. Patent and Trademark Office.

Azura Ophthalmics Ltd. announced that the company was awarded a grant from CUREator, Australia’s national biomedical incubator managed by Brandon BioCatalyst.

Azura Ophthalmics Ltd. today announced positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD).